FS2 Safety and Tolerability Study in Healthy Volunteers
Status:
Completed
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
Background Scarring typically occurs after trauma, burn injury or surgery. Hypertrophic
scarring presents as raised, red and itchy lesions which variably respond to various
treatment modalities, such as corticosteroids, pressure garments, laser therapy, the use of
silicone sheets and radiotherapy.
Kynurenine, or "Fibrostop 1" (FS1), and its further breakdown products, such as kynurenic
acid, or "Fibrostop 2" (FS2), are endogenous products found in many systems and have shown
potential in reducing scar formation in animal studies.
The aim of study is to evaluate the safety and tolerability of FS2 cream applied to the skin
of healthy human subjects.
Phase:
Phase 1
Details
Lead Sponsor:
British Columbia Professional Firefighters' Burn and Wound Healing Laboratory